Children have been exposed to unjustifiable risks that in some cases amount to research abuse. Powerful, financially interconnected stakeholders control all facets of research, including the approval process. Physician investigators, their academic institutions, and institutional review boards (IRBs) all come under the influence of funding sponsors, whose interests conflict with the best interest of children. Children cannot rely on IRBs or on any of the existing research oversight agencies to protect them, for research too often takes inordinate risks in the name of the greater good.
Get full access to this article
View all access options for this article.
References
1.
ABC News. (2002, May 29). Bitter medicine: Pills, profit, and the public health. Retrieved January 25, 2003, from http://www.ahrp.org/infomail/0502/30.html
2.
Adrian, N. (2001). Explosive outbursts associated with methylphenidate. [Letter]Journal of the American Academy of Child and Adolescent Psychiatry, 40, 618.
3.
Advisory Commission on Human Radiation Experiments (ACHRE). (1995). Chapter 7: The context for nontherapeutic research with children. Final report. Retrieved January 25, 2004, from http://tis.eh.doe.gov/ohre/roadmap/achre/chap7_2.html
4.
Alderman, J., Wolkow, R., Chung, M., & Johnston, H.F. (1998). Sertraline treatment of children and adolescents with obsessive—compulsive disorder or depression: Pharmacokinetics, tolerability, and efficacy. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 386—394.
5.
Altman, L. (2003, Aug. 8). New study links hormones to breast cancer risk. The New York Times, p. 1.
6.
American Academy of Pediatrics. (1995). Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics, 95, 286—294.
7.
American Medical Association, Council on Ethical and Judicial Affairs. (1994). Opinion E-6.03. Fee splitting: Referrals to health care facilities. [Originally issued 1977 , updated June 1994 and June 1996] Retrieved February 2, 2004from http://www.ama-assn.org/apps/pf_online/pf_online?f_n=browse&doc=policyfiles/CEJA/E-6.03.HTM&&s_t=&st_p=&nth=1&prev_pol=policyfiles/CEJA/E-5.09.HTM&nxt_pol=policyfiles/CEJA/E-6.01.HTM&
8.
American Medical Association. (2000— 2001). E-8.0315. Managing conflicts of interest in the conduct of clinical trials. Retrieved February 20, 2004, from http://www.ama-assn.org/ama/pub/category/8471.html
9.
Anas, G. (1985). The Anything Goes school of human experimentation . The Hastings Center Report, 15, 15—17.
10.
Anderson, G.M., Segman, R.H., & King, R.A. (1995). Serotonin and suicidality: The impact of fluoxetine administration. II. Acute neurobiological effects. Israel Journal of Psychiatry and Related Sciences, 32, 44—50.
11.
Angell, M. (2000). Is academic medicine for sale?The New England Journal of Medicine, 342, 1516—1518.
12.
Bailey, L.L., Nehlsen, C., Sandra, L., Concepcion, W., & Jolley, W.B. (1985). Baboon-to-human cardiac xenotransplantation in a neonate. Journal of theAmerican Medical Association, 254, 3321—3329.
13.
Best Pharmaceuticals for Children Act of 2002, P.L. 107-19-09.
14.
Birch, D.M., & Cohn, G. (2001, June 23—26). Of patients and profits. [Series] . Baltimore Sun. Retrieved October 1, 2003 , from http://www.baltimoresun.com/news/health/balte.research25jun25.story?coll=bal%2Dhome%2Dheadlines
15.
Black, K., Shea, C., Dursun, S., & Kutcher, S. (2000). Selective serotonin reuptake inhibitor discontinuation syndrome: Proposed diagnostic criteria. Journal of Psychiatry and Neuroscience, 25, 255—261.
16.
Bodenheimer, T. (2000). Uneasy alliance—clinical investigators and the pharmaceutical industry. The New England Journal of Medicine , 342, 1539— 1544.
17.
Boseley, S. (2003, Sept. 20). 50,000 children taking antidepressants . The Guardian. Retrieved January 25, 2004 , from http://www.guardian.co.uk/uk_news/story/0,3604,1045902,00.html
18.
Burton, T.M. (2002, May 17). Why cheap drugs that appear to halt fatal sepsis go unused. The Wall Street Journal, p. 1.
19.
Campbell, E.G., Weissman, J.S., Clarridge, B., Yucel, R., Causino, N.D., & Blumenthal, D. (2003). Characteristics of medical school faculty members serving on institutional review boards: Results of a national survey. Academic Medicine, 78, 831—836.
20.
Castellanos, F.X., Elia, J., Kruesi, M.J., Gulotta, C.S., Mefford, I.N., Potter, W.Z., et al. (1994). Cerebrospinal fluid monoamine metabolites in boys with attention deficit hyperactivity disorder. Psychiatry Research, 52, 305—316.
21.
Castellanos, F.X., Elia, J., Kruesi, M.J.P., Marsh, W.L., Gulotta, C.S., Potter, W.Z., et al. (1996). Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with ADHD. Neuropsychopharmacology , 14, 125—137.
22.
Cherland, E., & Fitzpatrick, R. (1999). Psychotic side effects of psychostimulants: A 5-year review. Canadian Journal of Psychiatry, 44, 811—813.
23.
Couzin, J. (2003, June 20). Brave new world. Science , 300, 1162—1165.
24.
Cowley, G., Springen, K., Leonard, E.Z., Robins, K., & Gordon, J. (1990, March 26). Prozac: A breakthrough drug for depression . Newsweek, pp. 42—45.
25.
Coyle, J.T. (1997). Biochemical development of the brain: Neurotransmitters and child psychiatry. In C. Popper (Ed.), Psychiatric pharmacosciences of children and adolescents (pp. 3—25). Washington, DC: American Psychiatric Press.
26.
Coyle, J.T. (2000). Editorial: Psychoactive drug use in very young children. Journal of theAmerican Medical Association, 283, 159—160.
27.
Creaney, W., Murray, I., & Healy, D. (1991). Antidepressant-induced suicidal ideation. Human Psychopharmacology, 6, 329—332.
28.
Dembner, A. (2001a, February 18). Dangerous dosage. The Boston Globe, p. A-1. Retrieved December 3, 2003, from http://www.boston.com/dailyglobe2/049/nation/Dangerous_dosageP.shtml
29.
Dembner, A. (2001b, March 20). Should a healthy child ever be a test subject?The Boston Globe, p. C-3. Retrieved January 25, 2004, from http://www.boston.com/dailyglobe2/079/science/Should_a_healthy_child_ever_be_a_test_subjectP.shtml
30.
Dembner, A. (2001c, March 20). Teddy bears and veiled threats. The Boston Globe, p. C-1. Retrieved January 25, 2004, from http://www.boston.com/dailyglobe2/079/science/Teddy_bears_and_veiled_threatsP.shtml
31.
Diller, L. (2000, February 2). Over-medicating America's kids. The Washington Post, p. A21.
32.
Dobbs, L. (2003, October 2). Over-medication: A growing crisis. Tallahassee Democrat. Retrieved December 3, 2003, from http://www.tallahassee.com/mld/democrat/news/opinion/6908288.htm?template=content-Modules/printstory.jsp
33.
Eichenwald, K. & Kolata, G. (1999, May 16). Drug trials hide conflicts for doctors . The New York Times, p. 1.
34.
Eli Lilly summary company profile. (2003). Business Week online. Retrieved June 15,2003, from http://research.businessweek.com/business_summary.asp?Symbol=LLY
35.
Emslie, G.J., Rush, A.J., Weinberg, W.A., Kowatch, R.A., Hughes, C.W., Carmody, T., et al. (1997). A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry,54, 1031—1037.
36.
Fleischman, A. (2002, May) Report of children's workgroup to NHRPAC clarifying specific portion of 45C.F.R. 46 Subpart D that governs children's research , Washington, DC. Retrieved December 3, 2003, from http://ohrp.osophs.dhhs.gov/nhrpac/documents/nhrpac16.pdf
37.
Food and Drug Administration Modernization Act of 1997, P.L. 105-115.
38.
Freedman, B., Fuks, A., & Wejer, C. (1993). In loco parentis: Minimal risk as an ethical threshold for research upon children. The Hastings Center Report, 23, 13—19.
39.
Friedman, R.A. (2003, Aug. 12). What you do know can't hurt you. The New York Times, p. A17.
40.
Geddes, J.R., Freemantle, N., Mason, J., Eccles, M.P., & Boynton, J. (2000). SSRIs versus other antidepressants for depressive disorder. Cochrane Database System Review, 2, CD001851.
41.
Glantz, L. (1998). Research with children. American Journal of Law and Medicine, 24, 213—244.
42.
GlaxoSmithKline. (2003). Letter to healthcare professionals in the UK. Retrieved January 25, 2004, from http://www.ahrp.org/risks/PaxilRisks0603.html
43.
Glenmullen, J. (2000). Prozac backlash. New York: Simon & Schuster.
44.
Grimes v. Kennedy Krieger Institute, 366 Md. 29; 782 A.2d 807 (Md. Ct. App. 2001).
45.
Grinfeld, M. (1998). Psychoactive medications and kids: New initiatives launched. Psychiatric Times, 14(3), 69.
46.
Harris, G.A. (2003, August 7). Debate resumes on the safety of depression's wonder drugs. The New York Times, p. 1. Retrieved from http://www.nytimes.com/2003/08/07/health/07DEPR.html
47.
Healy, D. (1994). The fluoxetine and suicide controversy: A review of the evidence. CNSDrugs, 2, 252—254.
48.
Healy, D. (1997a). The antidepressant era. Cambridge. MA: Harvard University Press.
49.
Healy, D. (1997b, October 5). Declaration submitted to the U.S. District Court, District of Hawaii in Forsyth v. Eli Lilly and Company, CV-95-00185 ACK.
50.
Healy, D. (2000). Antidepressant-induced suicidality. Primary Care Psychiatry, 6, 23—28.
51.
Healy, D. (2002, April). Testingpsychotropic drugs in children. Alliance for Human Research Protection. Retrieved January 25, 2004, from http://www.ahrp.org/children/healy0402.html
52.
Healy, D. (2003, June 20). Briefing submitted to Medicines and Healthcare Products Regulatory Agency (MHRA).
53.
Hyman, S.E., & Nestler, E.J. (1996). Initiation and adaptation: A paradigm for understanding psychoactive drug action. American Journal of Psychiatry,153, 151—162.
54.
Institute of Medicine. (2002). Responsible research: A systems approach to protecting research subjects. Washington, DC: Author.
55.
Kassirer, J.P. (2001). Financial conflict of interest: An unresolved ethical frontier. American Journal of Law and Medicine, 27, 149—162.
56.
Kauffman, M., & Julien, A. (2000, April 9). Surge in corporate cash taints the integrity of academic science. Hartford Courant, p. 1.
57.
Khan, A., Warner, H.A., & Brown, W.A. (2000). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database. Archives of General Psychiatry,57, 311—317.
58.
King, R.A., Riddle, M.A., Chappell, P.B., Hardin, M.T., Anderson, G.M., Lombroso, P., et al. (1991). Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 179—186.
59.
Kirsch, I., Moore, T.J., Scoboria, A., & Nicholls, S.S. (2002). The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention and Treatment, 5. Retrieved July 15, 2002, from http://journals.apa.org/prevention/volume5/pre0050023a.html
60.
Koerner, B. (2002, July—August). Disorders made to order. Mother Jones. Retrieved July 25, 2002, from http://www.motherjones.com/magazine/JA02/disorders.html
61.
Kouris, S. (1998). Methylphenidate-induced obsessive—compulsiveness . Journal of the American Academy of Child and Adolescent Psychiatry, 37, 135.
62.
Kushner, T.K., Belliotti, R. (1985). BabyFae: A beastly business. Journal of Medical Ethics, 114, 178—183.
63.
Lambert, N.M., & Hartsough, C.S. (1998). Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD subjects . Journal of Learning Disabilities, 31, 533—544.
64.
Lemmens, T., & Miller, P.B. (in press). The human subjects trade: Ethical and legal issues surrounding recruitment incentives. Journal of Law, Medicine, and Ethics .
65.
Lind, L. (1990). Finder's fees for research subjects. The New England Journal of Medicine, 303, 192—195.
66.
Maryland Court of Appeals. (2001a, Sept. 17). Amici curiae briefs in support of motion for reconsideration. Erica Grimes v. Kennedy Krieger Institute and Myron Higgins v. Kennedy Krieger Institute. 782 A.2d 807 (No. 128). Retrieved September 30, 2001, from http://www.hopkinsmedicine.org/press/2001/SEPTEMBER/briefs.htm
67.
Maryland Court of Appeals. (2001B, Oct. 1). Amicus curiae brief in opposition of appellee's motion for reconsideration. Grimes v. Kennedy Krieger Institute and Higgins v. Kennedy Krieger Institute. 782 A.2d 807 (No. 128). Retrieved December 15, 2003, from http://www.ahrp.org/children/AmicusKKI.htm
68.
Milne, C.P. (2001, April). The pediatric studies incentive: Equal medicines for all [White Paper]. Boston: Tufts Center for the Study of Drug Development.
69.
Morin, K., Rakatansky, H., Riddick, Jr, F.A., Morse, L.J., O'Bannon III, J.M., Goldrich, M.S., et al. (2002). Managing conflicts of interest in the conduct of clinical trials. Journal of the American Medical Association , 287, 78—84.
70.
Moore, T.J. (1997, December). Hard to swallow. TheWashingtonian . Retrieved from http://www.washingtonian.com/health/hardtoswallow.html
71.
Moss, M. (1996, June 12). A U.S. experiment on young children ignites painful debate. Wall Street Journal, p. 1.
72.
National Bioethics Advisory Commission. (2001 ). Ethical and policy issues in research involving human subjects (Vol. 1). Bethesda, MD: Author.
73.
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. (1979, April 18). The Belmont report (GPO 887-809). Washington, DC: U.S. Government Printing Office.
74.
National Human Research Protections Advisory Committee. (2001, August) Comment letter to the FDA on 45 CFR 46 Subpart D 408c. Retrieved February 5, 2004, from http://ohrp.osophs.dhhs.gov/nhrpac/documents/fda.pdf
75.
National Institutes of Health. (1998). Diagnosis and treatment of attention deficit hyperactivity disorder. NIH consensus statement. 16(2), 1—37. Retrieved January 30, 2003 from http://odp.od.nih.gov/consensus/cons/110/110_statement.html
76.
Nuremberg Code. (1947). Trials of war criminals before the Nuremberg Military Tribunals under Control Council Law No. 10 (Vol. 2, pp. 181—182). Washington, DC: U.S. Government Printing Office.
77.
Office of Human Research Protection. (2000 , Nov. 3). Letter of determination to the National Institutes of Health re: Protocol 96-Ch0101. Retrieved December 15, 2003 , from http://ohrp.osophs.dhhs.gov/detrm_letrs/nov00a.pdf
78.
Office of Protection from Research Risks (OPRR). (2001). Compliance oversight investigations resulting in restrictions/actions to institutions that have multiple project assurances (MPA) between January 1990—June 2000. Retrieved from http://www.ahrp.org/ethical/compliance.html
79.
Pfizer. (1996, May 23). Safety evaluation and epidemiology. Suicide-related behavior in children and adolescents in the sertraline OCD clinical development program . (Available from the U.S. Food and Drug Administration under the Freedom of Information Act)
80.
Pfizer. (1997, Oct. 20). Expert report on the clinical documentation of sertraline hydrochloride for obsessive compulsive disorder in pediatric patients. (Available from the U.S. Food and Drug Administration under the Freedom of Information Act)
81.
Preda, A., MacLean, R.W., Mazure, C.M., & Bowers, M.B. (2001). Antidepressant associated mania and psychosis resulting in psychiatric admission. Journal ofClinical Psychiatry , 62, 30—33.
82.
Prince v. Massachusetts, 321 U.S. 158, 170 (1944).
83.
Ravenel, S.D. (2002). A new behavioral approach to ADD/ADHD and behavioral management without medication. Ethical Human Sciences and Services, 4(2).
84.
Relman, A.S., & Angell, M. (2002, December 16). America's other drug problem. The New Republic, pp. 27—41.
85.
Roig-Franzia, M. (2001, Aug. 24). “My kids were used as guinea pigs .” The Washington Post, p. 1. Retrieved December 15, 2003, from http://www.washingtonpost.com/wp-dyn/articles/A59479-2001Aug24.html
86.
Ross, L.F. (2003). Do healthy children deserve greater protection in medical research? Journal ofPediatrics, 14, 108—112.
87.
Safer, D., Zito, J.M., & Fine, E.M. (1996). Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics, 98, 1084—1088.
88.
Saletu, B., Grunberger, J., & Linzmayer, L. (1986). On central effects of serotonin re-uptake inhibitors: Quantitative EEG and psychometric studies with sertraline and zimelidine. Journal of Neural Transmission, 67, 241—266.
89.
Sharav, V.H. (2002). Conflicts of interest [Presentation]. U.S. Army Medical Department and The Henry M. Jackson Foundation For The Advancement Of Military Medicine. Retrieved from December 15, 2003, from http://www.ahrp.org/testimonypresentations/armymeddept.html
90.
Sharav, V.H. (2003a). Children in clinical research: A conflict of moral values. American Journal of Bioethics, 31. Retrieved February 20, 2003, from http://bioethics.net/in_focus/sharav.pdf
91.
Sharav, V.H. (2003b). The impact of the FDA Modernization Act on the recruitment of children for research. Ethical Human Sciences & Services, 5(2), 83—108.
92.
Sherman, C. (2002, August 30). Antisuicidal effect of psychotropics remains uncertain. Clinical Psychiatry News, p. 1.
93.
Steinbrook, R. (2002). Testing medications in children. The New England Journal of Medicine, 347, 1462—1470.
94.
Steklow, S., & Johannes, L. (1997, Aug. 15). Test case: Drug makers relied on clinical researchers who now await trial—Two professors are accused of endangering patients and stealing $10 million. The Wall Street Journal , p. 1.
95.
TD v. NYS OMH, 626 N.Y.S.2d 1015 (1995).
96.
Teicher, M.H., Glod, C., & Cole, J.O. (1990a). Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry,147, 207—210.
97.
Teicher, M.H., Glod, C., & Cole, J.O. (1990b). Suicidal preoccupation during fluoxetine treatment [letter]. American Journal of Psychiatry,147, 1380— 1381.
98.
The need to test drugs on children. (2002, April 7). The New York Times, Sec. 4, p. 14.
99.
U.K. Department of Health. (2003, June 10). Press release: Seroxat, (Ref. 2003/ 0223).
100.
U.S. Department of Health and Human Services, Office of the Inspector General. (1998). Institutional review boards: A time for reform. Washington, DC: Author.
101.
U.S. Department of Health and Human Services, Office of the Inspector General. (2000). Recruiting human subjects: Pressures in industry-sponsored research. Washington, DC: Author.
102.
U.S. Department of Health, Education, and Welfare: Proposed regulations for children, 28 Fed. Reg. 31, 738 (1973).
103.
U.S. Drug Enforcement Agency. (2000, May 16). Congressional testimony, Committee on Education and the Workforce: Subcommittee on Early Childhood, Youth, and Families. Retrieved from http://www.usdoj.gov/dea/pubs/cngrtest/ct051600.htm
104.
U.S. Environmental Protection Agency. (1996 ). Lead-based paint abatement and repair and maintenance study in Baltimore: Pre-intervention findings (Report No. EPA-747-B-95-01). Washington, DC: U.S. Government Printing Office.
105.
U.S. Food and Drug Administration. (1998). Pediatric rule. Retrieved from http://www.fda.gov/cder/pediatric/pedethics-1199.htm
106.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. (2000). Pediatric depression: Background comments on pediatric depression. In Sample written requests for antidepressants. Retrieved December 3, 2003, from http://www.fda.gov/cder/pediatric/antidepressant_wr_template.htm
107.
U.S. General Accounting Office. (1996) Scientific research: Continued vigilance critical to protecting human subjects . Washington, DC: Author.
108.
U.S. General Accounting Office. (2001). Biomedical research: HHS direction needed to address financial conflicts of interest. Washington, DC: Author .
109.
Vitiello, B. (2001). Psychopharmacology for young children: Clinical needs and research opportunities. Pediatrics, 108, 983—990.
110.
Whitaker, R. (1998, November 17). The lure of riches fuels testing . The Boston Globe, p. 1.
111.
Wilens, T.E., Biederman, J., Kwon, A., Chase, R., Greenberg, L., Mick, E., et al. (2003). A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. Journal of Child and Adolescent Psychopharmacology, 13, 143—152.
112.
Willman, D. (2000, Dec. 20). Propulsid: A heartburn drug, now linked to children's deaths. Los Angeles Times, p. 1.
113.
Willson, D., & Heath, D. (2001, March 11—15). Uninformed consent [Series] . Seattle Times, p. 1.
114.
Wilson, M.A., Johnson, M.V., Goldstein, G.W., & Blue, M.E. (2000). Neonatal lead exposure impairs development of rodent barrel field cortex. Proceedings of the National Academy of Sciences of the United States of America, 97, 5540—5545.
115.
Wirshing, W., Van Putten, T., Rosenberg, J., Marder, S., Ames, D., & Hicks-Gray, T. (1992). Fluoxetine, akathisia, and suicidality: Is there a causal connection?Archives of General Psychiatry, 49, 580—581.
116.
Wyeth. (2003, Aug. 22). Dear healthcare professional. Retrieved from http://www.ahrp.org/infomail/03/09/02.html
117.
Young, G. (2001, August 28). Lead paint suit breaks new ground, sparks government investigation. The National Law Journal .
118.
Zimmerman, M., Mattia, J.I., & Posternak, M.A. (2002). Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? AmericanJournal Psychiatry, 159, 469—473.
119.
Zito, J.M., Safer, D. J., dos Reis, S., Gardner, J. F., Boles, J., & Lynch, F. ( 2000). Trends in the prescribing of psychotropic medications to preschoolers. Journal of theAmerican Medical Association , 283, 1025—1030.
120.
Zito, J.M., Safer, D. J., dos Reis, S., Gardner, J. F., Magder, L., Soeken, K., et al. (2003). Psychotropic practice patterns for youth: A ten-year perspective. Archives of Pediatrics and Adolescent Medicine , 157, 17—25.
